

Vaccine Confident Open Forum: The Latest COVID-19 Vaccine Recommendations

June 28, 2022

Pharmacists strengthening vaccine confidence in their patients and communities.

Host and Moderator

Michael Hogue, PharmD, FAPhA, FNAP
Dean and Professor,
Loma Linda University School of Pharmacy

Today's Focus

Discuss the latest COVID-19 vaccine recommendations, practical strategies for expanding immunizations to children under 5 years of age and how to manage questions from patients about their COVID-19 vaccine options.



CDC Acknowledgement

This accredited learning activity for pharmacists was developed by the American Pharmacists Association with support from the CDC.

This project was funded in part by a cooperative agreement with the Centers for Disease Control and Prevention (CDC) — CoAg number 1 NU50CK000576-01-00. The CDC is an agency within the Department of Health and Human Services (HHS). Contents of this resource do not necessarily represent the CDC or HHS and should not be considered an endorsement by the Federal Government.

Guest Speaker

John Grabenstein, RPh, PhD, FAPhA
Director for Scientific Communications,
Immunize.org
President, Vaccine Dynamics

Guest Speaker

Beverly Schaefer, RPh

Co-owner, Katterman's Sand Point Pharmacy

Seattle, WA

Speaker



Mitch Rothholz, RPh, MBA
Chief of Governance & State Affiliates,
American Pharmacists Association

Executive Director,
American Pharmacists Association Foundation

Disclosures

John Grabenstein, RPh, PhD, FAPhA, has provided the following disclosures:
Hourly consultant to Bavarian Nordic; CSL (Seqirus); JNJ (Janssen); Takeda; Valneva; VBI Vaccines

Mitchel C. Rothholz, RPh, MBA, has provided the following disclosures:
- Merck: Advisory board member, Spouse employer
- Pfizer: Advisory board member

All other individuals involved in the development of this material declare no conflicts of interest, real or apparent, and no financial interests in any company, product, or service mentioned in this program, including grants, employment, gifts, stock holdings, and honoraria. APhA's editorial staff declare no conflicts of interest or financial interests in any product or service mentioned in this activity, including grants, employment, gifts, stock holdings, and honoraria. For a complete list of APhA staff disclosures, please visit the APhA website at www.pharmacist.com/apha-disclosures.

Accreditation Information

The American Pharmacists Association is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education (CPE). This learning activity is approved for 1 hour of CPE credit (0.1 CEU). The ACPE Universal Activity Number for this live activity is 0202-0000-22-166-L06-P (pharmacists).

To obtain CPE credit for the live webinar, participants must be in attendance for the entire activity, enter the attendance code, and complete the speaker and course evaluations (My Training page) by August 27, 2022.

Initial Release Date: June 28, 2022
Target Audience: Pharmacists
Activity Type: Knowledge-based
Learning Level: 1

Learning Objectives

1. Review the latest COVID-19 vaccine products and recommendations for use.
2. Describe practical strategies for pediatric COVID-19 vaccination program implementation.
3. Discuss common concerns and questions and how they can be addressed to build vaccine confidence.



Open Forum Ground Rules

- Use the **Questions** field on the GoToWebinar toolbar to submit comments and questions related to the topic discussion.
- We will try to get to as many comments and questions as possible!
- Refer to the **Handout** in the GoToWebinar toolbar to access today's slides and links to resources.
- Today's **recording** will be made available soon



Discussion with John Grabenstein, Beverly Schaefer and Mitch Rothholz

Discuss the latest COVID-19 vaccine recommendations, practical strategies for expanding immunizations to children under 5 years of age and how to manage questions from patients about their COVID-19 vaccine options.

Celebrate!

Success after 18 months of COVID-19 vaccination!

- 255 million COVID-19 vaccinations given by community pharmacists and teams, Dec 2020—Jun 2022
- 43% of U.S. COVID-19 vaccinations given by community pharmacists and teams, Dec 2020—Jun 2022
- > 50% of U.S. COVID-19 vaccinations overall given via pharmacist-led programs, Dec 2020—Jun 2022
- 8.1 million COVID-19 vaccinations given by pharmacists and teams at LTC facilities, Dec 2020—Apr 2021
- 2/3 drop - LTC resident COVID-19 deaths fell by 2/3 compared to all COVID-19 deaths, Dec 2020—Feb 2021
- 1.3 million vaccinations given by student pharmacists via “Operation Immunization,” Dec 2020—Jun 2021
- > 45 million patient specimens tested by pharmacists for COVID-19, Apr 2020—Feb 2022
- > 100,000 COVID-19 monoclonal antibody treatments provided by pharmacists, Nov 2020—Jun 2022

Source: see following slide



References

1. Government Accountability Office. COVID-19: HHS Agencies' Planned Reviews of Vaccine Distribution and Communication Efforts Should Include Stakeholder Perspectives. November 2021. www.gao.gov/assets/gao-22-104457.pdf
2. Centers for Disease Control & Prevention. The Federal Retail Pharmacy Program for COVID-19 Vaccination: A Collaboration Between the Federal Government, States and Territories, and 21 National Pharmacy Partners and Independent Pharmacy Networks Nationwide. www.cdc.gov/vaccines/covid-19/retail-pharmacy-program/index.html.
3. Centers for Disease Control & Prevention. COVID-19 Vaccine Access in Long-term Care Settings. www.cdc.gov/vaccines/covid-19/long-term-care/pharmacy-partnerships.html. Accessed 2022 June 5.
4. CDC. COVID-19 Vaccinations in the United States. https://covid.cdc.gov/covid-data-tracker/#vaccinations_vacc-total-admin-rate-total.
5. Federal Emergency Management Agency. Community Vaccination Centers Playbook, April 23, 2021. www.fema.gov/disaster/coronavirus/governments/community-vaccination-centers-playbook. Accessed 2022 June 5.
6. Traynor K. COVID-19 mass vaccination involves unusual venues. Am J Health Syst Pharm. 2021;78(13):1162–1164. doi.org/10.1093/ajhp/zxab185
7. Gregory N. Pharmacy leadership, expertise imperative for successful COVID-19 vaccine rollout. Am J Health Syst Pharm. 2021;78(14);1264-1266. doi.org/10.1093/ajhp/zxab187
8. Gregory N. COVID-19 vaccines in tribal communities save lives, preserve culture. Am J Health Syst Pharm. 2021;78(10):835–839. doi.org/10.1093/ajhp/zxab105
9. Traynor K. Health systems quickly vaccinated communities against COVID-19 despite supply constraints. Am J Health Syst Pharm. 2021;78(11):940–942. doi.org/10.1093/ajhp/zxab158
10. Traynor K. COVID-19 Dispatch: Lifespan, Rhode Island. May 3, 2021. www.ashp.org/news/2021/05/04/rhode-island-pharmacist-earns-leadership-role-in-pandemic.
11. Conlen M, Mervosh S, Ivory D. Nursing homes, once hotspots, far outpace U.S. in Covid declines. *New York Times*, 2021 Feb 25, page A1. www.nytimes.com/interactive/2021/02/25/us/nursing-home-covid-vaccine.html. Accessed 2022 June 5.
12. American Pharmacists Association—Academy of Students of Pharmacy. Operation Immunization Annual Report, 2020-21: January 2022. Washington, DC.
13. National Association of Chain Drug Stores. Community Retail Pharmacies' Experience during the COVID-19 Response: Successes and Lessons Learned to Date, November 2021. www.nacds.org/pdfs/pharmacy/2021/CommunityRetailPharmaciesExperience-during-the-COVID-19-Response-Successes-and-Lessons-Learned-to-Date.pdf.
14. Goode JR, Page A, Burns A, Bernard S, Wheawill S, Gatewood SBS. The pharmacist's role in SARS-CoV-2 diagnostic testing. J Am Pharm Assoc. 2020 Nov-Dec;60(6):e19-e32. doi.org/10.1016/j.japh.2020.08.017.
15. Federal Emergency Management Agency. By the Numbers – Coronavirus Pandemic Whole-of-America Response. March 8, 2021. https://content.govdelivery.com/attachments/USDHSFEMA/2021/03/09/file_attachments/1717220/By%20the%20Numbers.COVID.FINAL.Mar.%208.2021.pdf.
16. Centers for Disease Control & Prevention. Increasing Community Access to Testing (ICATT) for COVID-19. Feb 4, 2022. www.cdc.gov/icatt/index.html.



Novavax COVID-19 Vaccine candidate

Synonyms:	NVX-Cov2373
Type:	Spike protein subunit with adjuvant
Adjuvant:	Matrix-M – 40-nm particles (*Quillaja saponaria* + cholesterol + phospholipid)
Production:	Baculovirus/Sf9-cell expression system, like Sanofi's *FluBlok*^{TM} influenza vaccine recombinant
Dosage Form:	Suspension, 5 mcg protein + 50 mcg Matrix-M per 0.5 mL
Storage:	Refrigerate
Regimen:	Days 0 + 21, 0.5 mL, intramuscular
Clinical Trials:	Phase 3: n=29,960, US and México, start Dec'20, PREVENT-19
Vaccine Efficacy:	18+ y/o, any infection: 90.4% (CI: 83, 95%), 7+ d after dose 2
	18+ y/o, moderate to severe: 100% (87, 100%)
Status:	EUA requested Jan 2022, VRBPAC recommends EUA Jun 2022, awaiting FDA decision
	WHO EUL Listing, 17 Dec 2021
	Emergency Access: Canada, Australia, EU, Switzerland, UK, *et cetera*

Source: Dunkle et al. *N Engl J Med* 2022; 386:531-543. DOI: 10.1056/NEJMoa2116185.
Plus Novavax reports

COVID-19 Vaccine Uses for Children

Why Vaccinate?

Children suffer and die from COVID-19: 6 months – 4 years alone:

- > 2.5 million infections, > 20,000 hospitalizations, > 200 deaths
- Multisystem inflammatory syndrome in children (MIS-C)
- These are rates higher than from influenza and other diseases that can now be prevented by vaccination.
- Almost half of parents of children < 5 yo say they left a job or changed schedules to care for a COVID-19-infected child.
- Some parents will want to “wait and see.” Remind them that the virus is circulating while they are waiting.

Sources: CDC ACIP presentations, 17-18 June 2022
https://www.cdc.gov/vaccines/acip/meetings/slides-2022-06-17.html and ... /slides-2022-06-18.html

COVID-19 Vaccine Uses for Children

Authorized by FDA and Recommended by CDC/ACIP

Age Group	Manufacturer	Dosing	Dosing Schedule	Booster Doses
12 y – 17 y	Pfizer-BioNTech	2 doses @ 30 mcg	days 0 + 21 (3-8 wks)	Yes, 5 mo later
5 y – 11 y	Pfizer-BioNTech	2 doses @ 10 mcg	days 0 + 21 (3-8 wks) .	Yes, 5 mo later
6 mo – 4 y	Pfizer-BioNTech	3 doses @ 3 mcg	days 0 + 21 (3-8 wks) + 8 weeks later	Not yet
			Label Issues: "2y—<5y" and "discard 6 h" Immunocompromised: add extra dose(s)	

Age Group	Manufacturer	Dosing	Dosing Schedule	Booster Doses
12 y – 17 y	Moderna	2 doses @ 100 mcg	days 0 + 28 (4-8 wks)	Not yet
6 y – 11 y	Moderna	2 doses @ 50 mcg	days 0 + 28 (4-8 wks)	Not yet
6 mo – 5 y	Moderna	2 doses @ 25 mcg	days 0 + 28 (4-8 wks)	Not yet
Sources: CDC, Moderna, Pfizer-BioNTech			Label Issues: age range Immunocompromised: add extra dose(s)	*23 Jun 2022*

See CDC. Use of COVID-19 Vaccines in the U.S.: Interim Clinical Considerations (https://www.cdc.gov/vaccines/covid-19/clinical-considerations/covid-19-vaccines-us.html) and FDA EUA COVID-19 Vaccine Fact Sheets (https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/covid-19-vaccines) for more detail.

Pfizer-BioNTech COVID-19 Vaccine

cvdvaccine-us.com

Description	Dilute Before Use	Do Not Dilute	Dilute Before Use	Dilute Before Use
Age Group	12 years and older	12 years and older	5 through 11 years ("Age 5y to <12y" on vial label)	6 months through 4 years (See information in maroon above the table.)
Vial Cap Color	Purple 	Gray 	Orange 	Maroon 
Dose	30 mcg	30 mcg	10 mcg	3 mcg
Dose Volume	0.3 mL	0.3 mL	0.2 mL	0.2 mL
Amount of Diluent Needed per Vial*	1.8 mL	NO DILUTION	1.3 mL	2.2 mL
Doses per Vial	6 doses per vial (after dilution)	6 doses per vial	10 doses per vial (after dilution)	10 doses per vial (after dilution)
Emergency Use Authorization (EUA) Fact Sheet	Click here	Click here	Click here	Click here
Storage Conditions				
Ultra-Low-Temperature (ULT) Freezer [-90°C to -60°C (-130°F to -76°F)]	12 months†	12 months‡	12 months‡	12 months‡
Freezer [-25°C to -15°C (-13°F to 5°F)]	2 weeks	DO NOT STORE	DO NOT STORE	DO NOT STORE
Refrigerator [2°C to 8°C (35°F to 46°F)]	1 month	10 weeks	10 weeks	10 weeks
Room Temperature [8°C to 25°C (46°F to 77°F)]	2 hours prior to dilution (including any thaw time)	12 hours prior to first puncture (including any thaw time)	12 hours prior to dilution (including any thaw time)	12 hours prior to dilution (including any thaw time)
After First Puncture [2°C to 25°C (35°F to 77°F)]	Discard after 6 hours	Discard after 12 hours	Discard after 12 hours	Discard after 12 hours§

*Diluent: sterile 0.9% Sodium Chloride Injection, USP. Bacteriostatic saline or other diluents must NOT be used.

†Regardless of storage condition, purple cap vaccine should not be used past the 12-month expiry. For vials with expiry dates of October 2021 through March 2022, the printed date on the label/carton reflects 6-month expiry. For vials with expiry dates of June 2022 through December 2022, the printed date on the label/carton reflects 9-month expiry. The vaccine should not be used past the 12-month (updated) expiry date as noted in the Fact Sheet.

MODERNA COVID-19 VACCINE PRESENTATIONS

Age Group	6 months through 5 years (*Primary Series*)	6 years through 11 years (*Primary Series*) *Currently unavailable (Use the vial with dark blue cap and a label with a purple border)*	6 years through 11 years (*Primary Series*) 18 years and older (*Booster Dose*)	12 years and older (*Primary Series*) 18 years and older (*Booster Dose*)
Vial Cap Color	Dark Blue	Dark Blue	Dark Blue	Red
Vial Label Border Color	**MAGENTA**	**TEAL**	**PURPLE**	**LIGHT BLUE**
Vial Image				
Primary Dose Volume	0.25 mL	0.5 mL	0.5 mL	0.5 mL
Booster Dose Volume	None	None	0.5 mL	0.25 mL
For storage and expiry information, see FDA-authorized Fact Sheet or scan QR code.	www.modernatx.com/covid19vaccine-eua	www.modernatx.com/covid19vaccine-eua	www.modernatx.com/covid19vaccine-eua	www.modernatx.com/covid19vaccine-eua

Moderna COVID-19 Vaccine

fda.gov/media/159306/download



APhA Resources

pharmacist.com/Practice/COVID-19/COVID-19-Vaccines

vaccineconfident.pharmacist.com



Guide to COVID-19 Vaccination Schedules

APhA COVID-19 RESOURCES: KNOW THE FACTS

This resource summarizes key information about COVID-19 vaccination schedules. Reference CDC's Clinical Considerations for Use of COVID-19 Vacci for detailed information and recommendations.

Table 1: FDA-authorized or approved COVID-19 vaccine options

Vaccine Product	Age Requirement	Vial Cap Color	Dilution Requirement	Primary Series	Booster Dose
Pfizer-BioNTech	≥ 12 years		1.8 mL 0.9% NaCl Inj.	0.3 mL (30 mcg)	
Pfizer-BioNTech	≥ 12 years		Do NOT dilute	0.3 mL (30 mcg)	
Pfizer-BioNTech	5–11 years		1.3 mL 0.9% NaCl Inj.	0.2 mL (10 mcg)	N/A
Moderna	≥ 18 years		Do NOT dilute	0.5 mL (100 mcg)	0.25 mL (50 mcg)
Moderna	≥ 18 years		Do NOT dilute	N/A	0.5 mL (50 mcg)
Janssen (J&J)	≥ 18 years		Do NOT dilute	0.5 mL ($5x10^{10}$ viral particles)	0.5 mL ($5x10^{10}$ viral particles)



CDC Resources

cdc.gov/vaccines/covid-19/clinical-considerations/covid-19-vaccines-us
cdc.gov/vaccines/covid-19/info-by-product/index





Immunize.org Resources

immunize.org/covid-19
immunize.org/express
immunize.org/subscribe

Checklist of Current Versions of U.S. COVID-19 Vaccination Guidance and Clinic Support Tools

Information current as of 11 p.m. ET on 02 JUNE 2022

This checklist, which is **updated at least monthly**, provides links to key COVID-19 vaccination resources and indicates when they were last updated (as of the date shown above).

- View this checklist online at www.immunize.org/catg.d/p3130.pdf to access the resources directly
- For a comprehensive index of COVID-19 vaccine information, go to www.immunize.org/covid-19

Primary CDC Guidance on Use of COVID-19 Vaccines

Web page	Date last updated
Use of COVID-19 Vaccines in the United States: Interim Clinical Considerations	20 May 2022
COVID-19 ACIP Vaccine Recommendations	31 May 2022

…VID-19 Immunization Schedule *(print ready PDF document)*

Schedule	Date last updated
…erim COVID-19 Vaccine Immunization Schedule for Ages 5 Years and Older	01 June 2022

…ct Sheets and Package Inserts

…: FACT SHEETS for Vaccines with Emergency Use Authorization (EUA)

Product	Age Range	Date last updated	
		For Healthcare Providers	For Recipients & Caregivers*
…zer-BioNTech, orange cap	5 through 11 years	17 May 2022	17 May 2022
…zer-BioNTech, purple cap	12+ years	01 June 2022	17 May 2022
…zer-BioNTech, gray cap	12+ years	17 May 2022	17 May 2022
…oderna, red cap, light blue …rder label (primary series and …5 mL booster dose)	18+ years	29 March 2022	29 March 2022
…oderna, dark blue cap, purple …rder label (0.5 mL booster …se only)	18+ years	29 March 2022	29 March 2022
…nssen (J&J)	18+ years	05 May 2022	05 May 2022

…ovide to each recipient or caregiver in place of Vaccine Information Statement (VIS) at time of vaccination

…: PACKAGE INSERTS for Approved (Licensed) Vaccines

Press Releases

Published on Thursday, June 2, 2022

Majority of pharmacists prepared to administer COVID-19 vaccine to children under 5, APhA survey finds

WASHINGTON, DC—The majority of responding pharmacists (66%) would be prepared to administer COVID-19 vaccines to children under 5 years old if authorized to do so, according to a recent survey of pharmacists conducted by the American Pharmacists Association (APhA).

Nearly half of respondents (44%) said they are currently planning to vaccinate based on community needs and abilities of pharmacy teams following FDA and CDC authorization and guidance. Pharmacists' level of vaccination engagement for this age group will be an individual practice and practitioner decision. As always, pharmacists stand ready to work with other immunization stakeholders.

"The data show that pharmacists are again poised to contribute to our nation's health efforts and vaccinate all Americans against COVID-19," said Scott J. Knoer, PharmD, MS, FASHP, APhA executive vice president and CEO. "This has been true since the first COVID-19 vaccines arrived in December 2020, and it continues to be the case today despite the enormous challenges facing pharmacists in every practice venue."

CDC recently reported that 70% of COVID-19 vaccinations have occurred in pharmacies, including 60% of adolescent vaccinations and 46% of vaccinations in children 5 to 11 years old.

The survey of 612 pharmacists was conducted from February 12, 2022, to March 1, 2022, with respondents from all regions of the country and representing a wide range of practice types, including chain pharmacies, independent pharmacies, and supermarket pharmacies. The margin of error in this survey is ±3.9% at the 95% confidence level.

66%

of responding pharmacists are prepared to administer COVID-19 vaccines to children under 5 years

as of March 2022

Access the survey

VaccineConfident.Pharmacist.com



Authority to Provide COVID-19 Vaccines

- **Pharmacists**, **pharmacy technicians**, **student pharmacists**, and **retired pharmacists**; subject to certain requirements
- Authorized to provide FDA-authorized or FDA-licensed COVID-19 vaccines according to ACIP COVID-19 vaccine recommendations to **patients 3 years or older**
- **Pharmacists must:**
  - Must complete the **immunization training requirement** in their state; if the licensing state does not specify training, an ACPE-approved practical training program of at least 20 hours is required
  - Current certificate in **basic CPR**
  - Must complete a **minimum of 2 hours of ACPE-approved, immunization-related CE** during each state licensing period. APhA's Pharmacy-Based Immunizations for Pediatric Patients is designed to meet this requirement.
  - Must comply with **recordkeeping** requirements
  - Must inform the patient and the adult caregiver accompanying the patient of the importance of a **well-child visit**

- Reference APhA's resource on Authority to Immunize During COVID-19

Well-child Visit Templates

[Well-Child Visit Brochure (PDF)]
[Template Referral Form Well-Child Visit (Word)]
[Well-Child Checkup Letter (Word)]



Importance of Well Child Visits –
Keeping Your Kids Healthy

It is important to get a personal primary care provider and to use the same practitioners as much as possible for your child's healthcare needs. The members of your child's healthcare team, that incudes primary care providers, pharmacists and other healthcare professionals, are focused on the well-being of your child. A personal primary care provider:

...ou get care for your child
...s care when your child is sick
...your child's medical history as well as your family history
...track of your child's medical services, such as immunizations (shots)
...ou important information about your child's growth and development
...your child to a specialist when needed
...o coordinate your child's health needs

...important, even when children are healthy. Well child visits will help to keep ...Your child's primary care provider will evaluate your child's general health, ...pment. Your child's primary care provider will also give you information and ...ded medical services, such as:

...exams
...such as vision, hearing and lab services
...(vaccinations)
...creening (children under 3 years or as needed for older children)
...g growth and development
...l referrals to specialists, if needed

...gular well child visits, your child's primary care provider can often detect and ...blems before they become more serious.

...mary care provider will review your child's health and family history. Well child ...ur child get to know the primary care provider and they can get to know you ...y will also maintain keep your child's medical record and coordinate care with ...your child's healthcare team, including your pharmacist.

APhA AMERICAN PHARMACISTS ASSOCIATION NASPA NCPA

Date of Birth:_____/_____/_____

Referral Form for Well-Child Visit

Patient Name (First/Last): _____

Referring Pharmacist: _____email:_____

Pharmacy Practice:_____Phone Number: _____

FAX Number: _____

Email: _____ Date of Referral: _____

Signature:_____**Date:** _____

The above patient was seen in our pharmacy/practice today and the following vaccines administered. The patient was informed regarding the importance of well-child visits. Additional items needing potential follow-up are indicated below. Feel free to contact us if you have further questions. We would appreciate receiving an update after you have seen the patient so that our records are current and we can support your treatment plan. We have submitted the vaccines we gave today to the state/local immunization information system (IIS).

Reason for Referral: ☐ **Well-child checkup** ☐ **Other follow-up**

The following vaccine(s) were administered today:	**Patient may need additional immunization(s)**
❑ DTaP ❑ Hep A ❑ Hep B ❑ Hib ❑ HPV ❑ Influenza ❑ MMR ❑ Meningococcal ❑ Pneumococcal (PCV) ❑ Polio (IPV) ❑ Rotavirus ❑ Td / Tdap ❑ Varicella ❑ Other: _____	❑ _____ ❑ _____ ❑ _____ **Comment:**
❑ **Comments / Observations:**	

[TEMPLATE – to be placed on pharmacy letterhead

Date **xx/xx/200x**

Dear **Name of Patient**,

You have taken an important step in protecting your child from infectious disease through vaccination. Your pharma... important part of your healthcare team and strives to colla... providers to best meet your child's individual healthcare n... your pharmacist provides important services related to yo... medications and overall health, having a primary care pro... important. A primary care provider oversees your child's c... well-being.

As children develop, well-child visits with your child's prim... offers a time to review and discuss each of the important ... child's physical, cognitive, emotional, and social developm... ongoing relationship with a primary care provider, ensures ... health and medical needs will be identified and addressed ... can assist in coordinating tests, checkups and follow up c...

Ask your pharmacist for assistance in finding a primary c... your community if you do not currently have one.

[Pharmacist]

APhA

VaccineConfident

VaccineConfident.Pharmacist.com


Sand Point Village


CHECK IN
FOR
FLU SHOTS

Getting Ready

- THINK about how immunizing toddlers and infants is different than immunizing adults and get prepared
- STRATEGIZE about the pharmacy physical layout for vaccine area for kids and which vaccines to offer
- SCHEDULE immunizations with an appointment calendar—may want to choose special days
- RECRUIT volunteers to help you on immunization days

Initial Encounter

- Tell the parent to have a seat and hold the child on their lap
  - If the child is old enough, ask if they want the immunization in the arm or the leg
  - They have no choice about getting it, but a choice about *where*
- Don’t tell them the immunization won’t hurt—tell them it will be quick
- Ask the parent to hold (really hold) the child’s hands
- Once seated and hand holding, be quick about the process

Finishing the Process

- Prep the area intended for administration
- Have all supplies ready to go—vaccine drawn up, alcohol swab ready, band-aid peeled and ready to place
- As you inject the vaccine, ask a question—it helps break the concentration on the needle
- Allow time for possible physical struggling before and for comforting afterward. Also, questions and concerns from the parent. You may want to set aside a space for this, so you can move on to the next child.
- Let volunteers help with COVID cards and rewards



Keys to Success!

Open Forum Discussion

Your Comments, Questions, Feedback



APhA

VaccineConfident

Review of APhA's Ongoing Activities

What You Need to Know



APhA VaccineConfident

Take Action! Federal Provider Status Legislation

Equitable Community Access to Pharmacist Services (ECAPS) Act

- H.R. 7213
- Introduced in 2022
- Establishes pharmacists as eligible providers under Medicare Part B and path for reimbursement:
  - **Test**: COVID, flu, RSV, strep
  - **Treat**: COVID, flu, strep
  - **Immunize**: COVID, flu
  - Certain pharmacist **services for public health emergency or need or close gaps in health equity**
- Limited by state scope of practice



Learn more & contact your legislators today!
pharmacist.com/Advocacy/Issues/Provider-Status

ICYMI: Pulse on Practice & Policy

[Pulse on Practice & Policy Open Forum Series]

Access the recording to hear from experts how this legislation could help expand access to pharmacists' services and address gaps in health equity.

[Register] for our upcoming open forum on **Thursday, July 14th from 12-1pm ET**!

Building Vaccine Confidence

Building vaccine confidence in others is challenging unless you are confident in the COVID-19 vaccines. Begin by learning key information about vaccine confidence and the COVID-19 vaccines and then prepare to build vaccine confidence in others by accessing s and outreach strategies.

In Yourself and the Team

Vaccine confidence starts with a strong foundational knowledge of how COVID-19 vaccines work from science and research to development, approval, and administration. With the right tools and information, you can develop vaccine confidence as a pharmacist or member of the pharmacy team.

BUILD CONFIDENCE IN YOURSELF >

In Your Patients and the Community

Reach vaccine hesitant patients in your communities armed with the latest information. Have productive conversations, answer common questions and build confidence in the efficacy and safety of COVID-19 vaccines. Find the resources you need to have a positive impact on developing and building vaccine confidence in your patients.

Designed to help you:

- Stay informed
- Be inspired
- Build confidence

Patient Resources

Access a library of information and resources to help you plan for community outreach and access downloadable patient-friendly information you can print and share.

ACCESS THE LIBRARY >



APhA Vaccine Confident Playbook

The APhA Vaccine Confident Playbook is a user-friendly, action-oriented resource to inform pharmacist–patient conversations regarding COVID-19 vaccines, with the goal of reducing vaccine hesitancy, bolstering vaccine confidence, and increasing vaccine uptake.

TOPICS ^

BROWSE PLAYBOOK >

VaccineConfident.Pharmacist.com

APhA

VaccineConfident

VaccineConfident.Pharmacist.com